Evaluation of the Clinical Features and Laboratory Data of Patients with Severe Eosinophilic Asthma Classified as Super-Responders, Partial Responders, or Nonresponders to Mepolizumab Treatment: A Real-Life Study
International Archives of Allergy and Immunology · 2023
DOI: 10.1159/000529760 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Archives of Allergy and Immunology, 2023. Verfasst von Mehmet Erdem Cakmak und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy and Clinical Immunology, Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey. Hauptthemen laut MEDLINE: Anti-Asthmatic Agents, Asthma, Pulmonary Eosinophilia. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Introduction
Mepolizumab is a treatment option in patients with severe eosinophilic asthma, which inhibits interleukin-5. The aim of this study was to evaluate the clinical features and laboratory data of patients with severe eosinophilic asthma who were classified as super-responders, partial responders, or nonresponders to mepolizumab treatment.
Methods
In this retrospective real-life study, the clinical features and laboratory data were compared between groups of patients with severe eosinophilic asthma who were classified as super-responders, partial responders, or nonresponders to mepolizumab treatment.
Results
Evaluation was made of a total of 55 patients, comprising 17 (30.9%) males and 38 (69.1%) females with a mean age of 51.28 ± 14.32 years. All the patients were receiving mepolizumab treatment for severe eosinophilic asthma, with 17 (30.9%) patients evaluated as super-responders, 26 (47.3%) as partial responders, and 12 (21.8%) as nonresponders. After mepolizumab treatment, there was a statistically significant decrease in asthma exacerbations, the number of oral corticosteroids (OCSs) used, the rate of hospitalization due to asthma attacks, and the eosinophil count (cells/µL) (p < 0.001, p < 0.001, p < 0.001, and
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Allergy and Clinical Immunology, Başakşehir Çam and Sakura City Hospital, Istanbul, Turkey.
Zitieren
APA
Cakmak, M. E., Öztop, N., Yeğit, O. O., & Özdedeoğlu, Ö. (2023). Evaluation of the Clinical Features and Laboratory Data of Patients with Severe Eosinophilic Asthma Classified as Super-Responders, Partial Responders, or Nonresponders to Mepolizumab Treatment: A Real-Life Study. International Archives of Allergy and Immunology. https://doi.org/10.1159/000529760
Vancouver
Cakmak ME, Öztop N, Yeğit OO, Özdedeoğlu Ö. Evaluation of the Clinical Features and Laboratory Data of Patients with Severe Eosinophilic Asthma Classified as Super-Responders, Partial Responders, or Nonresponders to Mepolizumab Treatment: A Real-Life Study. International Archives of Allergy and Immunology. 2023. doi:10.1159/000529760
BibTeX
@article{Cakmak2023,
author = {Cakmak, Mehmet Erdem and Öztop, Nida and Yeğit, Osman Ozan and Özdedeoğlu, Özlem},
title = {Evaluation of the Clinical Features and Laboratory Data of Patients with Severe Eosinophilic Asthma Classified as Super-Responders, Partial Responders, or Nonresponders to Mepolizumab Treatment: A Real-Life Study},
journal = {International Archives of Allergy and Immunology},
year = {2023},
doi = {10.1159/000529760}
}
EUVIMED